Aura Biosciences Files 8-K

Ticker: AURA · Form: 8-K · Filed: 2024-09-12T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, regulatory-filing

TL;DR

Aura Biosciences filed an 8-K, but the key details are missing from this snippet.

AI Summary

Aura Biosciences, Inc. filed an 8-K on September 12, 2024, to report on other events and financial statements. The filing does not contain specific financial figures or details about the 'other events' in the provided text.

Why It Matters

This filing indicates Aura Biosciences is making a regulatory submission, but the specific details of the events or financial statements are not disclosed in this excerpt.

Risk Assessment

Risk Level: low — The filing is a standard 8-K without immediate disclosed financial impact or significant corporate changes in the provided text.

Key Players & Entities

FAQ

What is the exact date of the earliest event reported in this 8-K filing?

The earliest event reported is September 12, 2024.

What is the state of incorporation for Aura Biosciences, Inc.?

Aura Biosciences, Inc. is incorporated in Delaware.

What is the SIC code for Aura Biosciences, Inc.?

The Standard Industrial Classification (SIC) code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

What is the filing date of this 8-K report?

The filing date is September 12, 2024.

What are the principal executive offices of Aura Biosciences, Inc.?

The principal executive offices are located at 80 Guest Street, Boston, Massachusetts, 02135.

Filing Stats: 1,259 words · 5 min read · ~4 pages · Grade level 15.3 · Accepted 2024-09-12 06:50:35

Key Financial Figures

Filing Documents

Forward Looking Statements

Forward Looking Statements Statements contained under this Item 8.01 regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements about the initiation, timing, progress, results, and cost of the Company's research and development programs and the Company's current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and the Company's research and development programs; statements regarding the Company's expectations for an improved quality of life of patients after treatment with bel-sar; the Company's ability to successfully manufacture its drug substances and product candidates for preclinical use, for clinical trials and on a larger scale for commercial use, if approved; the ability and willingness of the Company's third-party strategic collaborators to continue research and development activities relating to the Company's development candidates and product candidates; the Company's ability to commercialize its products, if approved; the Company's ability to obtain funding for its operations necessary to complete further development and commercialization of its product candidates; the Company's ability to obtain and maintain regulatory approval of its product candidates; the size and growth potential of the markets for the Company's product candidates, and the Company's ability to serve those markets; the Company's financial performance; the Company's expected cash runway into the second half of 2026; and the implementation of the Company's business mod

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release Dated September 12, 2024. 99.2 Corporate Presentation of the Company. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aura Biosciences, Inc. Date: September 12, 2024 By: /s/ Julie Feder Julie Feder Chief Financial Officer

View on Read The Filing